Skip to Main Content

Paper Details

Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
Leukemia
27
2022
ALL, Cas9, RZ-2994, SHMT, SHMT1, SHMT1/2, SHMT2, T, T-, T-ALL, T-ALL cell lines, T-cell ALL, T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, cancers, folate, formate, leukemia, methotrexate, one, one-carbon, purine, pyrimidine, relapsed/refractory disease, serine, serine hydroxymethyltransferases 1 and 2
Author NameAffiliation
Yana PikmanDana-Farber Cancer Institute, Boston Children's Hospital
Gabriela AlexeDana-Farber Cancer Institute, Boston Children's Hospital
Gabriela AlexeBoston University
Gabriela AlexeBroad Institute of Massachusetts Institute of Technology and Harvard University
Gabriela AlexeDana-Farber Cancer Institute, Boston Children's Hospital
Gabriela AlexeBroad Institute of Massachusetts Institute of Technology and Harvard University
Gabriela AlexeBoston University
Angela SuINSERM UMR , St Louis Hospital
Jun QiDana-Farber Cancer Institute
Giovanni RotiUniversity of Parma
Alexandre PuissantINSERM UMR , St Louis Hospital
Kimberly StegmaierDana-Farber Cancer Institute, Boston Children's Hospital
Kimberly StegmaierBroad Institute of Massachusetts Institute of Technology and Harvard University
Kimberly StegmaierDana-Farber Cancer Institute, Boston Children's Hospital
Kimberly StegmaierBroad Institute of Massachusetts Institute of Technology and Harvard University
  • 1 - 15

Datasets

Release 1.2